Stock markets are fixated on Fed policy, but two experts believe investors should forget the U.S. central bank for now.» Read More
Oncologists, aware that patients are paying the costs of expensive cancer drugs, are declining to prescribe medicines that have scant or no effect.
#1 biotech and pharma stock picks
CNBC's Bertha Coombs tracks the Nasdaq as the index briefly followed the Dow and S&P 500 in recovering September's losses with a biotech boost.
Express Scripts, the largest pharmacy benefits manager in the U.S., says it's got a plan to fight drug price increases: Refuse to pay.
The nation's largest pharmacy benefit manager plans to control costs from new cholesterol drugs through discounts and restricting use.
Axovant Sciences CEO Vivek Ramaswamy discusses how his company could lead the way to a treatment for Alzheimers.
CNBC's Bertha Coombs reports on what is dragging down the biotech sector.
Another big selloff in biotech, as the IBB is down more than 5 percent today. Are there still opportunities in the sector or is it just too risky right now? With Duncan Rolph, Miracle Mile Advisors.
U.S. biotech shares extended their downward spiral on Tuesday as concerns about drug pricing continued to plague the sector.
CNBC's Bertha Coombs reports on biotech's 6 percent drop on the day.
William Reinsch, president of the National Foreign Trade Council (NFTC), expects Congress to vote on the Trans-Pacific Partnership (TPP) deal in April or May next year.
Spark Therapeutics will apply for U.S. approval of its single treatment for genetic blindness, reports CNBC's Meg Tirrell.
Spark Therapeutics plans to file for U.S. regulatory approval next year for the first gene therapy product on the market in the U.S.
CNBC's Meg Tirrell reports Spark Therapeutics will apply for U.S. approval of its single treatment for genetic blindness.
Savita Subramanian, head of U.S. equity and quantitative strategy, BofA Merrill Lynch, says the S&P 500 is the most "liquid play on generally high quality companies."
Novocure shares tumble in Nasdaq debut
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
The real problem with biotech has to do with the size of biotech firms, says industry CEO Robert Mulroy. Here's why.
Michael Thompson, managing director for Global Markets Intelligence at S&P Capital IQ, says there is still scope to replace labour with capital through technological advances, especially in industries such as healthcare.
Neera Tandan, Center for American Progress president, weighs in on the best ways to control prices in the prescription drug market and encourage company's to put money into research and development rather than marketing.
Get the best of CNBC in your inbox